Characterizing the molecular signatures induced by oncolytic measles virus along with conventional therapies in experimental glioma

Abstract

Scientific Objectives 1. To determine the feasibility of oncolytic virotherapy using MeV in glioblastoma through characterization of glioma cell lines and primary glioblastoma cell cultures in vitro. 2. To identify a synergistic combination of MeV with SOC, radiotherapy and alkylating chemotherapy in glioma cell lines (LN229 and LNZ308), glioma stem-like cells (GS8) and temozolomide-resistant LN229 cells (R-LN229) in vitro. 3. To characterize and validate the molecular mechanisms of synergy in the combinatorial treatment regimen through transcriptome analysis using RNA sequencing. 4. To delineate the treatment-induced immunological profile of MeV-infected glioma cells established through presentation of antigens using HLA ligandome analysis.